Page last updated: 2024-08-21

quinazolines and celecoxib

quinazolines has been researched along with celecoxib in 42 studies

Research

Studies (42)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	31 (73.81)	29.6817
2010's	11 (26.19)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X	1
Blackhall, F; Danson, S; Papakotoulas, PI; Thatcher, N	1
Altundag, K; Altundag, O; Boruban, C; Silay, YS	1
Dannenberg, AJ; Gibson, N; Lippman, SM; Subbaramaiah, K	1
Chen, A; Chen, ZG; Choe, MS; Khuri, FR; Lin, Y; Shin, DM; Shin, HJ; Sun, SY; Wieand, HS; Zhang, X	1
Haddad, RI; Joshi, VA; Lee, JC; Lindeman, NI; Norris, CM; Posner, MR; Wirth, LJ; Zhao, X	1
Bertagnolli, MM; Carothers, AM; Hunt, DH; Javid, SH; Moran, AE; Redston, M	1
Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH	1
Nelson, NJ	1
Dubinett, SM; Elashoff, RM; Figlin, RA; Krysan, K; Milne, GL; Morrow, JD; Newman, RA; Reckamp, KL; Tucker, C	1
Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H	1
Cho, KH; Cho, MJ; Jun, HJ; Lee, JS; Park, JS; Pyo, H; Zo, JI	1
Ballabh, P; Braun, A; Csiszar, A; Goldman, SA; Hu, F; Lou, N; Nedergaard, M; Rivera, A; Smith, K; Ungvari, Z; Xu, H	1
Gadgeel, SM; Heath, EI; Heilbrun, LK; Ruckdeschel, JC; Venkatramanamoorthy, R; Wozniak, A	1
Chen, Z; Choe, MS; Klass, CM; Shin, DM; Zhang, X	1
Buchanan, FG; DuBois, RN; Holla, V; Katkuri, S; Matta, P	1
Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A	1
Chen, L; He, Y; Huang, H; Liao, H; Wei, W	1
Dohadwala, M; Dubinett, SM; Elashoff, D; Figlin, RA; Gardner, BK; Inge, L; Krysan, K; Mao, J; Rajasekaran, A; Reckamp, KL; Sharma, S	1
Agarwala, A; Breen, T; Bruetman, D; Einhorn, LH; Fisher, W; Hanna, N; Juliar, B; McClean, J; Taber, D; Titzer, M; Yu, M	1
Argiris, A; Basu, S; Bonomi, P; Buckingham, L; Coon, J; Fidler, MJ; Johnson, DH; Kaiser, K; Patel, JD; Sandler, A; Villaflor, VM	1
Ahmad, A; Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH	1
Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N	1
Bergmann, F; Breinig, M; Ehemann, V; Esposito, I; Fischer, L; Friess, H; Herpel, E; Höpfner, M; Kern, MA; Kleeff, J; Köhler, C; Rieker, RJ; Schirmacher, P	1
Davies, JM; Goldberg, RM	1
Ciou, SC; Hong, JH; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Wang, LH	1
Bissonette, R; Brown, PH; Hill, J; Hilsenbeck, SG; Kittrell, F; Medina, D; Zhang, Y	1
Abba, MC; Aldaz, CM; Bissonnette, RP; Brown, PH; Gaddis, S; Hill, J; Hu, Y; Kittrell, FS; Levy, CC; Medina, D	1
Batra, RK; Dubinett, SM; Limsukon, A; Soo Hoo, GW; Susanto, I	1
Li, SS; Qiu, Y; Shu, X; Tian, Y; Xie, L; Xu, J; Zhang, X	1
Li, RK; Liao, J; Qiang, O; Wang, CH	1
Chen, CT; Genden, EM; Gupta, V; Gurudutt, V; Kao, J; Misiukiewicz, K; Packer, SH; Rivera, M; Teng, M; Tong, CC	1
Booth, L; Chen, CS; Cruickshanks, N; Dent, P; Grant, S; Ridder, T	1
Bell, R; Khasraw, M	1
Amin, AR; Beitler, JJ; Brandes, JC; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, WJ; Khuri, FR; Kono, S; Lewis, M; Moreno-Williams, R; Müller, S; Nannapaneni, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Thomas, SM; Zhang, H	1
Beitler, JJ; Chen, AY; Chen, Z; Chen, ZG; Grandis, JR; Grist, W; Hurwitz, SJ; Khuri, FR; Kono, SA; Lewis, M; Moore, CE; Moreno-Williams, R; Müller, S; Nannapaneni, S; Owonikoko, TK; Ramalingam, S; Saba, NF; Shin, DM; Shin, HJ; Sica, G; Yang, CS; Zhao, Y	1
Wirth, LJ	1
Dong, XL; Dong, Z; Li, G; Li, XL; Mu, XY; Ni, YH; Sun, EL; Sun, J; Yi, Z	1
Chen, JM; Chen, S; Du, W; Huang, W; Liu, J; Liu, RY; Pan, C; Shen, J; Wu, J; Zhou, L; Zhou, Y; Zhu, X	1
Gong, P; Li, H; Li, J; Li, N; Ma, X; Su, F	1
Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG	1

Reviews

3 review(s) available for quinazolines and celecoxib

Article	Year
Perspectives on novel therapies for bronchial carcinoma. Expert opinion on pharmacotherapy, 2005, Volume: 6, Issue:7 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Vascular Endothelial Growth Factor A	2005
First-line therapeutic strategies in metastatic colorectal cancer. Oncology (Williston Park, N.Y.), 2008, Nov-30, Volume: 22, Issue:13 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Camptothecin; Capecitabine; Celecoxib; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Humans; Irinotecan; Leucovorin; Meta-Analysis as Topic; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Prognosis; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Treatment Outcome; Vitamin B Complex	2008
Primary systemic therapy in HER2-amplified breast cancer: a clinical review. Expert review of anticancer therapy, 2012, Volume: 12, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab	2012

Trials

10 trial(s) available for quinazolines and celecoxib

Article	Year
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-01, Volume: 23, Issue:28 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pyrazoles; Quinazolines; Sulfonamides	2005
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jun-01, Volume: 12, Issue:11 Pt 1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cohort Studies; Cyclooxygenase 2; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasm Staging; Pyrazoles; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides; Treatment Outcome	2006
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2007, Volume: 2, Issue:4 Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Confidence Intervals; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Platinum; Probability; Pyrazoles; Quinazolines; Risk Assessment; Sulfonamides; Survival Analysis	2007
Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemokines, CC; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Macrophage Inflammatory Proteins; Matrix Metalloproteinase 9; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides; Tissue Inhibitor of Metalloproteinase-1	2008
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:4 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles; Quinazolines; Sulfonamides; Survival Rate	2008
The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Apr-01, Volume: 14, Issue:7 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Hemorrhage; Humans; Immunohistochemistry; In Situ Hybridization; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Peptic Ulcer; Predictive Value of Tests; Pyrazoles; Quinazolines; Sulfonamides	2008
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors. Molecular cancer therapeutics, 2008, Volume: 7, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides	2008
Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer, 2011, Jul-15, Volume: 117, Issue:14 Topics: Adult; Aged; Aged, 80 and over; Celecoxib; Cyclooxygenase 2 Inhibitors; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Maximum Tolerated Dose; Middle Aged; Pyrazoles; Quinazolines; Radiation-Sensitizing Agents; Retreatment; Sulfonamides	2011
Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Mar-01, Volume: 19, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cell Movement; Cell Proliferation; Cyclooxygenase Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Head and Neck Neoplasms; Humans; Immunoenzyme Techniques; Mice; Mice, Nude; Prognosis; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Tumor Cells, Cultured	2013
Chemoprevention of head and neck cancer with celecoxib and erlotinib: results of a phase ib and pharmacokinetic study. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Disease Progression; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pyrazoles; Quinazolines; Sulfonamides	2014

Other Studies

29 other study(ies) available for quinazolines and celecoxib

Article	Year
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Sep-01, Volume: 10, Issue:17 Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins	2004
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands), 2005, Volume: 49, Issue:3 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome	2005
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides	2005
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; DNA-Binding Proteins; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Immunoblotting; Immunoenzyme Techniques; Membrane Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostaglandins E; Pyrazoles; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Sulfonamides; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2005
Deficient E-cadherin adhesion in C57BL/6J-Min/+ mice is associated with increased tyrosine kinase activity and RhoA-dependent actomyosin contractility. Experimental cell research, 2006, Feb-15, Volume: 312, Issue:4 Topics: Actin Depolymerizing Factors; Actomyosin; Adenomatous Polyposis Coli Protein; Amides; Animals; Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Cadherins; Calcium; Cardiac Myosins; Celecoxib; Cell Adhesion; Egtazic Acid; Enterocytes; ErbB Receptors; Focal Adhesion Kinase 2; GTP-Binding Protein alpha Subunits, G12-G13; Intestinal Mucosa; Intestine, Small; Lysophospholipids; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Microscopy, Electron, Transmission; Mitogen-Activated Protein Kinase 1; Muscle Contraction; Muscle Relaxants, Central; Myosin Light Chains; Phosphorylation; Protein Binding; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; rho GTP-Binding Proteins; rhoA GTP-Binding Protein; Sulfonamides; Tyrphostins; Up-Regulation	2006
Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Molecular cancer therapeutics, 2005, Volume: 4, Issue:12 Topics: Apoptosis; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Electrophoretic Mobility Shift Assay; ErbB Receptors; Erlotinib Hydrochloride; Humans; NF-kappa B; Pancreatic Neoplasms; Phosphorylation; Pyrazoles; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sulfonamides	2005
Years of research come to fruition with launch of oral cancer prevention trial. Journal of the National Cancer Institute, 2006, Jan-18, Volume: 98, Issue:2 Topics: Animals; Antineoplastic Agents; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Cyclooxygenase Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Membrane Proteins; Mouth Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor Cross-Talk; Signal Transduction; Sulfonamides	2006
[Molecular-targeted therapy for hormone-refractory prostate cancer]. Hinyokika kiyo. Acta urologica Japonica, 2006, Volume: 52, Issue:6 Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D	2006
Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Aug-15, Volume: 12, Issue:16 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Rabbits; Radiation Tolerance; Sulfonamides	2006
Paired drugs give advanced lung cancer a double punch. Health news (Waltham, Mass.), 2006, Volume: 12, Issue:9 Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Celecoxib; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Sulfonamides	2006
Angiogenic inhibition reduces germinal matrix hemorrhage. Nature medicine, 2007, Volume: 13, Issue:4 Topics: Aborted Fetus; Angiopoietin-2; Animals; Blotting, Western; Brain; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Endothelial Cells; Humans; Immunohistochemistry; Infant, Newborn; Infant, Premature; Intracranial Hemorrhages; Neovascularization, Physiologic; Piperidines; Pyrazoles; Quinazolines; Rabbits; Sulfonamides; Vascular Endothelial Growth Factor Receptor-2	2007
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, May-15, Volume: 13, Issue:10 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microtubules; Mitosis; Pyrazoles; Quinazolines; Sulfonamides; Taxoids	2007
Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer research, 2007, Oct-01, Volume: 67, Issue:19 Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Intestinal Polyps; Intestine, Small; Mice; Mice, Inbred C57BL; Oligonucleotide Array Sequence Analysis; Prostaglandins; Pyrazoles; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays	2007
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor. Cancer, 2007, Dec-15, Volume: 110, Issue:12 Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Prostaglandins E; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured	2007
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Medical oncology (Northwood, London, England), 2008, Volume: 25, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Bisbenzimidazole; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides	2008
Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer. Molecular cancer therapeutics, 2008, Volume: 7, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dinoprostone; DNA, Complementary; DNA, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorescence; Humans; Indoles; Mice; NF-kappa B; Pancreatic Neoplasms; Protein Binding; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Transfection; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays	2008
Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? The American journal of gastroenterology, 2009, Volume: 104, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Apoptosis; Blotting, Western; Carcinoid Tumor; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; ErbB Receptors; Female; Humans; Insulinoma; Male; Mice; Mice, Transgenic; Middle Aged; Pancreatic Neoplasms; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tyrphostins; Young Adult	2009
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells. Lung cancer (Amsterdam, Netherlands), 2009, Volume: 65, Issue:3 Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rad51 Recombinase; Sulfonamides	2009
Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:2 Topics: Animals; Anticarcinogenic Agents; Bexarotene; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Incidence; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Suppressor Protein p53	2009
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:2 Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Precancerous Conditions; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Protein, Translationally-Controlled 1; Tumor Suppressor Protein p53	2009
Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy. Chest, 2009, Volume: 136, Issue:3 Topics: Biopsy; Bronchoscopy; Celecoxib; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Laryngeal Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Papilloma; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides	2009
[The effect of simultaneously blocking target epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2 on the growth of NPC cell]. Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery, 2009, Volume: 23, Issue:18 Topics: Apoptosis; Celecoxib; Cell Division; Cyclooxygenase 2; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Tumor Cells, Cultured	2009
[Effects of EGFR inhibitor AG1478 in combination with celecoxib on the growth of gastric cancer cells]. Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2010, Volume: 41, Issue:4 Topics: Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Humans; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proliferating Cell Nuclear Antigen; Pyrazoles; Quinazolines; Stomach Neoplasms; Sulfonamides; Tyrphostins	2010
OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer biology & therapy, 2012, Volume: 13, Issue:14 Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; Beclin-1; Benzoquinones; Brain Neoplasms; Celecoxib; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Genes, erbB-1; Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lapatinib; Lipids; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; RNA Interference; RNA, Small Interfering; Signal Transduction; Sulfonamides	2012
Chemoprevention of squamous cell carcinoma of the head and neck: no time to lose momentum. Cancer prevention research (Philadelphia, Pa.), 2014, Volume: 7, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Chemoprevention; Erlotinib Hydrochloride; Female; Head and Neck Neoplasms; Humans; Male; Pyrazoles; Quinazolines; Sulfonamides	2014
Simultaneous blockage of epidermal growth factor receptor and cyclooxygenase-2 in a human xenotransplanted lung cancer model. Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:1 Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Quinazolines; Sulfonamides; Transplantation, Heterologous	2014
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib. Oncotarget, 2015, Aug-28, Volume: 6, Issue:25 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Neoplasms; Celecoxib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Female; G1 Phase; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Phosphorylation; Piperidines; Quinazolines; Xenograft Model Antitumor Assays	2015
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:8 Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines	2015
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer. Oncology reports, 2018, Volume: 40, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Prostatic Neoplasms; Quinazolines; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2018